CMS modified NCD 67 for cochleostomy with neurovascular transplant for Meniere's disease, effective January 9, 2026. Here's what billing teams need to know.
The Centers for Medicare & Medicaid Services updated National Coverage Determination NCD 67, which governs Medicare coverage of cochleostomy with neurovascular transplant as a treatment for Meniere's disease. The policy's position is unchanged in substance but has been formally modified as of January 9, 2026: Medicare does not cover this procedure. The policy does not list specific CPT or HCPCS codes. Any claim for cochleostomy with neurovascular transplant billed to Medicare will be denied.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Medicare) |
| Policy | Cochleostomy with Neurovascular Transplant for Meniere's Disease |
| Policy Code | NCD 67 |
| Change Type | Modified |
| Effective Date | January 9, 2026 |
| Impact Level | Medium — low procedure volume, but claim denial risk is absolute |
| Specialties Affected | Otolaryngology (ENT), Neurotology, Neurosurgery |
| Key Action | Audit your charge capture and payer contracts now; do not bill Medicare for this procedure |
CMS Cochleostomy with Neurovascular Transplant Coverage Criteria and Medical Necessity Requirements 2026
NCD 67 is a National Coverage Determination. That means it applies to all Medicare Administrative Contractors and all Medicare fee-for-service claims nationwide. There is no local coverage determination that overrides it. No MAC can authorize coverage for this procedure.
The CMS cochleostomy with neurovascular transplant coverage policy is blunt: Medicare does not cover this procedure, period. The basis is a lack of scientific evidence supporting its safety and effectiveness for treating Meniere's disease. CMS has not identified any clinical scenario in which medical necessity would establish coverage.
This matters for billing because medical necessity is the gateway to Medicare reimbursement on almost everything. Here, that gateway is closed by the NCD itself. Even a well-documented chart with a confirmed Meniere's diagnosis, failed medical therapy, and a surgeon's attestation will not get this claim paid. The procedure falls outside Medicare's covered benefits as defined by NCD 67 in the NCD Medicare system.
Cochleostomy with neurovascular transplant billing to Medicare is not a gray area. There is no prior authorization pathway, no clinical trial policy exemption mentioned in NCD 67, and no appeals argument built on medical necessity. If a patient wants this procedure, the conversation about financial responsibility needs to happen before the procedure — not after a denied claim.
CMS Cochleostomy with Neurovascular Transplant Exclusions and Non-Covered Indications
CMS recognizes two surgical procedures for Meniere's disease as legitimate treatment options when medical management fails. Decompression of the endolymphatic hydrops and labyrinthectomy are both recognized. Cochleostomy with neurovascular transplant is not in that group.
The NCD states directly that there is no scientific evidence supporting the safety or effectiveness of cochleostomy with neurovascular transplant for Meniere's disease or Meniere's syndrome. CMS uses both terms — "Meniere's disease" and "Meniere's syndrome" — throughout the policy. The coverage policy applies to both.
This is not a "not medically necessary for this patient" determination. It is a blanket non-coverage determination for the procedure itself. That distinction matters for how you counsel patients and structure your financial agreements.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Meniere's disease, medically refractory — cochleostomy with neurovascular transplant | Not Covered | No specific codes listed in NCD 67 | NCD applies nationwide; no MAC override possible |
| Meniere's disease — decompression of endolymphatic hydrops | Recognized surgical option (not governed by NCD 67) | Verify with applicable LCD or MAC guidance | Coverage subject to medical necessity and other payer billing guidelines |
| Meniere's disease — labyrinthectomy | Recognized surgical option (not governed by NCD 67) | Verify with applicable LCD or MAC guidance | Coverage subject to medical necessity and other payer billing guidelines |
CMS Cochleostomy with Neurovascular Transplant Billing Guidelines and Action Items 2026
The effective date for the modified NCD 67 is January 9, 2026. Use that date as your action trigger.
| # | Action Item |
|---|---|
| 1 | Pull any pending claims for cochleostomy with neurovascular transplant before they process. If your team has claims sitting in queue dated on or after January 9, 2026, pull them now. A denied claim creates more work than a held claim. |
| 2 | Add a hard stop to your charge capture system. Flag the procedure description for cochleostomy with neurovascular transplant so it generates a review alert before a claim goes to Medicare. The policy does not list specific CPT or HCPCS codes, so the flag needs to be based on the procedure description and operative note review, not just a code screen. |
| 3 | Issue an Advance Beneficiary Notice of Noncoverage (ABN) for every Medicare patient considering this procedure. The ABN is not optional when a procedure is non-covered under an NCD. Have the patient sign it before scheduling. This protects your practice and gives the patient a clear picture of their financial responsibility. |
| 4 | Audit your payer contracts for non-Medicare payers. CMS non-coverage under NCD 67 governs Medicare. Commercial payers may have different coverage positions on cochleostomy with neurovascular transplant. Check Aetna, Cigna, and UnitedHealthcare policies separately. Do not assume Medicare's non-coverage position reflects theirs. |
| 5 | Brief your ENT and neurotology physicians on the NCD language. Surgeons sometimes assume that a medically sound rationale creates a reimbursement path. It does not here. Make sure your medical director and any referring surgeons understand that cochleostomy with neurovascular transplant billing to Medicare will result in claim denial, regardless of documentation quality. |
| 6 | Review your financial counseling scripts. Patients who are Medicare beneficiaries and who are candidates for this procedure need to understand upfront that Medicare will not cover it. Your front-end team needs talking points that are accurate and compliant. |
If your practice sees high volumes of Meniere's disease patients and has been discussing cochleostomy with neurovascular transplant as a surgical option, loop in your compliance officer before January 9, 2026. The combination of a non-covered NCD procedure and Medicare patients creates real exposure if your processes are not buttoned up.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Cochleostomy with Neurovascular Transplant Under NCD 67
No Specific Codes Listed in NCD 67
The policy data for NCD 67 does not include specific CPT, HCPCS, or ICD-10 codes. CMS did not enumerate billing codes in the NCD document.
This creates a practical problem for cochleostomy with neurovascular transplant billing teams. Without a code list, you cannot build a simple code-based claim scrubber to catch these claims. Your edits need to work at the procedure description and documentation review level.
| Field | Detail |
|---|---|
| CPT Codes | None specified in NCD 67 |
| HCPCS Codes | None specified in NCD 67 |
| ICD-10-CM Codes | None specified in NCD 67 |
Contact your Medicare Administrative Contractor for guidance on how to code cochleostomy with neurovascular transplant procedures if you need to bill a non-covered service with a denial expected — for example, to generate a denial that a patient needs for secondary insurance purposes. Your MAC's provider relations team can clarify the appropriate code path for a known non-covered procedure under NCD 67 in the Medicare system.
The Bigger Picture: NCD 67 and Meniere's Disease Surgical Coverage in 2026
Meniere's disease is common enough that most ENT practices see it regularly. The surgical pathway for refractory cases is real. Decompression of the endolymphatic hydrops and labyrinthectomy are both recognized options. Cochleostomy with neurovascular transplant is the outlier.
The real issue here is that some procedures stay in clinical use long after payers have drawn a hard line. If surgeons at your facility are discussing cochleostomy with neurovascular transplant as an option for Medicare patients, your billing team needs to be part of that conversation now. Not after the claim denies. Now.
The modified NCD 67 does not change the underlying coverage position — Medicare has not covered this procedure. But a formal modification in January 2026 signals that CMS reviewed and reaffirmed this position. That makes it harder to argue the NCD was outdated or overlooked. It's current, active policy.
Whether Meniere's disease cochleostomy with neurovascular transplant is covered under Medicare is not an open question. NCD 67 answers it. Your job is to make sure your billing guidelines, charge capture, and patient financial counseling all reflect that answer.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.